A Snapshot of European Collection Schemes
International Journal of Basic & Clinical Pharmacology 5(6):2290-2294
DOI: 10.18203/2319-2003.ijbcp20164081
Drugs & Therapy Perspectives vol.36 (2020) 6
The International Pharmaceutical Federation (FIP) is the global body representing over 4 million pharmacists and pharmaceutical scientists. We work to meet the world's health care needs. FIP is a non-governmental organisation that has been in official relations with the World Health Organization sin...ce 1948.
more
The humanitarian-development-peace nexus (HDPNX) is a new way of working that offers a framework for coherent joined-up planning and implementation of shared priorities between humanitarian development and peacebuilding actors in emergency settings. To advance the HDPNx in a given country a sh...ared foundational understanding of the current situation is needed. However it can be challenging to find such a resource perpetuating poor understanding planning and operationalization. This is one of a series of country profiles that have been developed by WHO to address that need. Each profile provides an overview of health-related nexus efforts in the country and will be updated regularly.
more
22 Sept. 2021
The rapid development of effective Covid-19 vaccines in 2020 gave hope to the world in the darkest days of the deadly pandemic. However, the vaccine roll-out has been massively skewed towards wealthy nations. While rich states have hoarded vaccines, companies have also played a decisi...ve role in restricting fair access to a life-saving health product. This report focuses on six leading vaccine developers, AstraZeneca, BioNTech, Johnson & Johnson, Moderna, Novavax and Pfizer, assessing each company’s human rights policy, pricing structure, records on intellectual property, knowledge and technology sharing, allocation of available vaccine doses and transparency.
Available in Arabic, English, French, German and Spanish
more
This Pharmaceutical Country Profile for Kenya (2010) has been developed by the Ministry of Medical Services with support of the World Health Organization. The Profile contains information on existing socio-economic and health-related conditions, resources, regulatory structures and processes and out...comes relating to the pharmaceutical sector in Kenya.
more
Drug registration in Kenya started in 1982; the process mainly involves an evaluation committee at the Kenya Pharmacy and Poisons Board (PPB) that aims to approve products based on quality, safety and efficacy.
Antimicrobial resistance (AMR) is a global threat that requires urgent
collaborative action within and among countries. As a result of the worldwide reports of the increasing rates of AMR to hospital and community-acquired infections and in the agricultural sector, the Global Action Plan on AMR was... adopted in 2015. T
more
The APCA Atlas provides the most up-to-date information of palliative care development in nearly all countries in Africa, using indicators derived, rated, and chosen by in-country African experts followed by a thorough Delphi consensus process with a panel of international experts on palliative care... indicators
more
The Atlas of Palliative Care in the Eastern Mediterranean Region is the first systematic attempt to assess the status of resources, activities, and needs of palliative care in the region. It provides a comparative picture of the current state of palliative care in simple and clear graphics, utilisin...g texts, tables, figures and maps that reproduce information given by national palliative care leaders in the Eastern Mediterranean. This information is essential for the appropriate planning of the development of palliative care for this region.
more
Antimicrobial resistance (AMR) – the ability of microorganisms to resist antimicrobial treatments, especially antibiotics – has a direct impact on human and animal health and carries a heavy economic burden due to higher costs of treatments and reduced productivity caused by sickness. AMR is res...ponsible for an estimated 33,000 deaths per year in the EU. It is also estimated that AMR costs the EU €1.5 billion per year in healthcare costs and productivity losses.
more
The OIE has been working on the AMR issue for a long
time. In undertaking its role as a standard- setting organisation*
for animal health, including zoonoses, the OIE has developed
a wide range of international standards on antimicrobial
agents, in particular on responsible and prudent use.
The...se standards are regularly reviewed and updated
through the transparent and inclusive process of expert
advice and member consultation before presentation for
adoption to the World Assembly of Delegates from our
180 Member Countries each year. The OIE also works with
its Member countries in a comprehensive and continuous
capacity building process for their Veterinary Services.
more